+34 679 490 537info@nanbiosis.com

Posts on Jan 1970

Nanomol group initiates contact with the AEMPS to bring a new treatment against venous leg ulcers to the clinic

Researchers of the Nanomol group, ICMAB-CSIC and CIBER-BBN members of the ICTS “NANBIOSIS”, specifically of the Biomaterial Processing and Nanostructuring unit (U6), together with the company Nanomol Technologies S.L. have begun a consultation process with the Spanish Association of Medicines and Health Products (AEMPS) to try and enter a new treatment in a clinical studies stage, to fight against venous ulcers in lower extremities. The study is carried out within the framework of the RIS3CAT NANONAFRES project.

Approximately, 80% of ulcers in lower extremities have associated pathologies of venous insufficiency and these wounds are usually recurrent. An open ulcer can take from weeks to years to close, increasing the risk of mortality and affecting the quality of life of patients who suffer from them, mostly elderly people. The solution proposed within the NANONAFRES project consists of a medicine for topical application based on the incorporation of a biomolecule, with skin regenerating activity, encapsulated in nanoparticles. This approach ensures the protection of the active substance, preventing its degradation, while allowing the controlled and direct release of the drug in the area of ​​the ulcer.

The NANONAFRES project, led by Nanomol Technologies SL, was born from the collaboration of the Nanomol group from ICMAB-CSIC with the companies Nanomol Technologies and BIOMED-LEITAT, the primary care centres EAP Osona Sur-Alt Congost SLP and the EAP Vallcarca-Sant Gervasi, public hospitals such as the Terrassa Health Consortium and the Maresme Health-Consortium Foundation and international research centres such as the Centro de Ingeniería Genética y Biotecnología de Cuba. This project, awarded with a RIS3CAT fund sponsored by the Generalitat of Catalonia, has a budget of 2.3 million euros and a duration of 3 and a half years.

This first consulting meeting with the AEMPS is a very important milestone in the process of developing any drug, in order to carry out clinical trials and transfer the system to the market, and thus bring the proposed treatment to the people who need it.

This approach will improve the effectiveness of current venous ulcers treatments, as well as the quality of life of patients, reducing the cost of medicines available today. In addition, the Nanomol group already has an internationally granted patent on this product, which demonstrates the novelty of this system and strengthens its position to reach the market through the partners present in this consortium and, in particular, through its spin-off Nanomol Technologies S.L.

Links of interest:

Article published on ICMAB’s site: http://icmab.es/nanomol-participa-al-projecte-nanonafres-de-la-comunitat-ris3cat-de-nous-dispositius-de-diagnostic-i-big-data-aplicades-a-la-salut

Article published on LEITAT’s site: https://projects.leitat.org/nanonafres/

Patent: “VESICLES COMPRISING EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THEREOF” (WO2014019555)

Read More

Making the most from Signals in Biomedical applications.

Last week took place on Berlin the EMB Conference 2019, (the 41st  International Engineering in Medicine and Biology Conference) with the overarching theme “Biomedical engineering ranging from wellness to intensive care” counting with plenary keynotes from leading academic and industrial scientists, who presented aspects of innovation and translational engineering in biomedicine.

Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, from CIBER-BBN and I3A-UZ, was invited to give a talk on the topic “Phisiologically Driven Biomedical Signal Processing: making the most of Signals

Pablo Laguna has co-authored more than 150 research papers on this topic, over 300 international conference papers, and has advise 15 Ph.D Thesis. He has lead a broad number of projects on biomedical signal interpretation specially in the cardiovascular domain, most of them with international collaborations at clinical and engineering sites. He is having some international scientific responsibilities, as serving as past-president of the board of directors of Computing in Cardiology conference, editor of the digital signal processing journal (Eurasip), and of the Medical and Biological Engineering and Computing (springer), organizer of different scientific conferences, etc. He is also responsible of the Ph.D. program in Biomedical Engineering at Zaragoza University. He is Fellow of the IEEE. He is, together with L. Sörnmo, the author of Bioelectrical Signal Processing in Cardiac and Neurological Applications, book (Elsevier, 2005)

Read More

NANBIOSIS- OmicsTech: EXPLORING COLLABORATIONS BETWEEN ICTS FACILITIES

Last week, representatives of NANBIOSIS and OmicsTech met at the IQAC-CSIC facilities in Barcelona to exchange common research lines, points of view of their complementarity and collaboration possibilities of the facilities, both recognized as Unique Scientific Technical Infrastructure (ICTS) by the Spanish Government.

The Infrastructure for Omics Technologies OmicsTech ICTS is a distributed infrastructure that offers researchers the possibility of using globally competitive singular facilities exclusively dedicated to work with omics technologies, with a spectrum of biomolecular analysis tools for holistic capture of biological processes, to support research, technological development, and innovation activities. Advances in genomics, proteomics and metabolomics technologies have opened new avenues towards understanding molecular disease mechanisms and the behavior of cells, tissues, organs and, eventually, whole organisms. OmicsTech is formed by the Center of Omic Sciences (COS-URV-EURECAT), Centro Nacional de Análisis Genómico (CNAG-CRG) and the Proteomics Platform-CRG (PP-CRG-UPF).

The Infrastructure for the Production and Characterization of Nanomaterials, Biomaterials and Systems in Biomedicine NANBIOSIS ICTS is a distributed infrastructure for biomedical research with outsourcing equipment and expertise of excellence to design and produce biomaterials, nanomaterials and their nanoconjugates as well as their characterization from a physic-chemical, functional, toxicological and biological (preclinical validation) point of view, focused on biomedical applications such as: IVDs, medical devices, biosensors, regenerative medicine, drug delivery systems, therapeutic agents or MRI contrast agents. NANBIOSIS provides more than 700 accesses per year and services to 100 companies.

Due to this complementarity, both ICTS facilities have explored collaborations possibilities and a list of initiatives were discussed. This new collaboration will start with a session of OmicsTech in the Annual Conference of CIBER-BBN that will take place next October 21-22 in Tarragona. Meanwhile, both ICTS will work together stablishing synergies between different services that both institutions provide increasing the scope of the biomedical solutions given to the health sector. Collaboration between groups of the CIBER-BBN and groups related to OmicsTech will additionally facilitate the synergies between the two ICTS facilities.

For further information:

www.nanbiosis.es; www.omicstech.org

Read More

Agreement signed with Spanish Goverment for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, a projects related to the ICTS NANBIOSIS has been selected by the Ministry of Science, Innovation and Universities for co-financing with FEDER funds of the European Regional Development Funds program.

An agreement has been signed between Ministry of Science, Innovation and University of Extremadura, institution that houses NANBIOSIS unit 16 for the co-financing of the Project FICTS1420-14-09: “Compra e instalación y puesta a punto de equipamiento de caracterización para complementar la Unidad 16 de NANBIOSIS – Surface Characterization and Calorimetry Unit –NANBIOSISU16”.

Read More